Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Latest Patent to Complement Issued Claims on Viral Inhibition, Adaptive Immune Stimulation, and Brain Protection/Regeneration
The Company was previously awarded by the United States Patent and Trademark Office the following QuadraMune® related patents:
- Patent #11,229,674, covering inhibition of the immune suppressing enzyme indolamine 2,3 dioxygenase2. It is published that this enzyme plays a fundamental role in immune suppression by cancer3, as well as numerous viruses including SARS-CoV-2, the causative agent of COVID-194.
- Patent #11,266,707, “Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19”5.
- Patent #11,504,410, covering use of QuadraMune® and its derivatives for protecting and restoring brain function after neurological damage, including Long COVID6.
- Patent #11759495, covering upregulation of T regulatory cells for suppression of suicidal ideation7.
“In addition to this important validation from the USPTO, the fact that the ingredients in QuadraMune® have been reported by institutions such as
“Our Company is driven by a desire to address unmet medical needs, whether it is through developing state of the art stem cell and gene therapies, or science-backed nutraceuticals,” said
About
1 Cerwenka and Lanier. Natural killer cells, viruses and cancer. Nat Rev Immunol. 2001 Oct;1(1):41-9.
2 https://patents.google.com/patent/US11229674B1/
5 https://patents.google.com/patent/US11266707B2/
6 https://patents.google.com/patent/US11504410B2
7 https://patents.google.com/patent/US11759495B2/
8 Johns Hopkins University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304286293/en/
ir@tsoimail.com
Source: